Background: There is currently no single index for the diagnostic screening of hereditary spherocytosis (HS). However, hematology analyzers are widely used in hospital laboratories because of their highly automated performance and quality control procedure, and detection of some blood cell parameters may be useful for the early screening of HS.
| INTRODUC TI ON
Hereditary hemolytic anemia is the most common hematologic disease worldwide, while the reported frequency of glucose-6phosphate dehydrogenase (G6PD) deficiency is about 8% in malaria-endemic countries, equivalent to approximately 1.33 hundred million women and 2.2 hundred million men. 1 It is estimated that approximately 7% of the global population are carriers of inherited hemoglobin disorders. About 14 504 newborn infants suffer from hemoglobin H disease annually and 23 329 from severe thalassemia (THAL), most in developing countries. 2, 3 The incidence of hereditary spherocytosis (HS) in North America and northern Europe is 1/2000-1/5000. 4, 5 There are no available population census data regarding HS, but several related studies have been conducted. Li et al 6 Laboratory tests used to diagnose HS include red cell morphology examination, blood cell parameters, red cell osmotic fragility test, red cell membrane protein measurement, and membrane protein mutation detection. HS is characterized by an increased number of microspherocytes in the peripheral blood, with hyperchromatic small red cells being of particularly high diagnostic value. The presence of microcytic erythrocytes > 7.8% can be used for HS diagnosis with a sensitivity of 56.7% and specificity of 84.8%. 8 However, red cells shrink and are misshapen in patients with autoimmune hemolytic anemia (AIHA), and different numbers of microspherocytes may be present, thus reducing the specificity of red cell morphology for HS diagnosis. The current laboratory tests used to screen HS include the NaCl osmotic fragility test, acidified glycerol lysis test (AGLT), and sucrose hemolysis test. However, the NaCl osmotic fragility test has low sensitivity of 48%-95% because of different types of membrane protein deficiencies, making it unsuitable for screening of mild HS. 9 The sensitivity of the AGLT50 is higher than the NaCl osmotic fragility test; however, although AGLT50 is relatively short in patients with HS with a diagnostic sensitivity of 95%, 10 it is also shortened in patients with AIHA. 11 Regarding the sucrose hemolysis test, hemolysis > 2.8% has a diagnostic sensitivity of 78.7% and specificity of 95.3% for HS, 12 but is a complex procedure. A next-generation osmotic gradient ektacytometry (NG-OGE) assay was recently introduced for the screening of HS. The NG-OGE is useful for distinguishing HS from other hereditary red cell membrane disorders; however, it does not differentiate between HS and AIHA. 13, 14 Unfortunately, the new generation of ektacytometer is difficult to be applied in the clinical laboratory, mainly used in some research centers or specialized laboratories. Red blood cell membrane protein detection tests include the eosin-5'-maleimide binding test and sodium dodecyl sulfate-polyacrylamide gel electrophoresis test. The former has a sensitivity of 93% and specificity of 98% for the diagnosis of HS, 11 and the latter is more specific for protein 4.2-and ankyrin-deficient HS, but less specific for asymptomatic and mild HS, and is thus unsuitable for determining the type of membrane protein deficiency in approximately 10% of HS patients. 15 Gene mutations in HS are scattered, and no specific mutation sites suitable for screening have yet been identified.
Hematology analyzers are widely used in hospital laboratories because of their highly automated performance and quality control procedures, and some blood cell parameters may be suitable for early screening of HS. Mean corpuscular hemoglobin concentration (MCHC) was included as one of the diagnostic criteria for HS in guideline for the diagnosis and management of HS in 2004, 16 and mean sphered corpuscular volume (MSCV) has also been reported to have diagnostic value in HS. [17] [18] [19] Furthermore, we recently found that mean reticulocyte volume (MRV) was a valuable index for the diagnosis of HS. 20 In this study, we investigated the values of blood cell parameters including MRV, MSCV, MCHC, and absolute reticulocyte count (Ret)/immature reticulocyte fraction (IRF) for the screening and differential diagnosis of HS.
| MATERIAL S AND ME THODS

| Subjects
This study was approved by the Ethics Committees of the First 
| Equipment and methods
No therapeutic measures were given to patients in the HS group or the disease control group. Two milliliters of fasting venous blood was taken from each subject and transferred to an anticoagulation tube containing 10% EDTA-K2 (1.5 mg/mL) for analysis of red blood cell and reticulocyte parameters using a Coulter LH780 Hematology Analyzer (Beckman Coulter Inc, Fullerton, CA, USA).
During analysis, methylene-blue-stained red blood cells formed deproteinated spherocytes after treatment with an acidic hypoosmotic solution. The spherocytes could then be further divided into mature red blood cells and reticulocytes using the volume, conductivity, and light scatter technology. The mean volume of the spherocytes was measured as MSCV, and MCV, MCHC, MRV, and Ret of red blood cells and reticulocytes were detected simultaneously. The IRF was calculated by measuring the fluorescence intensity of RNA left in the reticulocytes using a Coulter LH780 Hematology Analyzer. 
| Statistical analysis
| RE SULTS
Blood cell parameters in the HS, disease control, and normal control groups are shown in Table 1 of HS was 0.92 (95% CI 0.88, 0.97), the sensitivity was 82.1%, and the specificity was 94.5% with a cutoff value of 334.9 g/L. The area under the ROC curve of Ret/IRF for diagnosis of HS was 0.77(95% CI 0.70, 0.84), the sensitivity was 65.7%, and the specificity was 81.0% with a cutoff value of 4.5.
| D ISCUSS I ON
In patients with HS, red blood cell membrane protein deficiency leads to membrane vesiculation and membrane loss, resulting in a greatly reduced membrane surface area. Because hemoglobin is lost very little compared to the loss of the red blood, and MCHC thus increases with increasing numbers of spherocytes. However, the diagnostic sensitivity and specificity of MCHC are not ideal, with MCHC > 347.0 g/L having a sensitivity of only 73.3% and specificity of 72.6% for the diagnosis of HS. 8 In addition, an increase in blood mesobilirubin levels interferes with MCHC detection, often leading to false-positive increases in MCHC levels. Different from the former study, our results showed that MCHC ≥ 334.9g/L had a diagnostic sensitivity of 82.1% and specificity of 94.5%, so it has higher specificity than the last. This may be related to the fact that the control group in this research is mainly the hemolytic anemia, while the increased MCHC is the feature to distinguish HS from other hemolytic anemias, such as THAL and AIHA.
Deproteinized spherocytes are formed after red blood cells are first dyed into new methylene blue and then processed in a kind of acid and hypotonic deproteinized solution. Next, spherocytes are divided into mature erythrocytes and reticulocytes by using VCS technology of Coulter LH780 Hematology Analyzer. 21 The average volume of all the reticulocytes is MRV, and the av- AIHA, and G6PD deficiency and identified MRV as a general and specific index for HS screening and for the differential diagnosis of different types of hemolytic anemia. 20 We also found that MRV ≤ 95.8 fl had a diagnostic sensitivity and specificity of 86.8% and 91.2%, respectively. In the current study, we compared several blood cell parameters for the screening and differential diagnosis of HS and found that the diagnostic value of MRV was second to that of MSCV-MCV. AIHA and G6PD deficiency are associated with acute hemolysis, leading to compensatory hyperplasia of reticulocytes and promoting the release of immature reticulocytes (prior type IV) and resulting in enlarged MRV. The pathological mechanism underlying THAL involves deletion and mutation of the globin gene, but does not include reduced membrane surface area. THAL thus mainly manifests as chronic hemolysis and anemia, and there was thus no significant difference in MRV between THAL patients and healthy controls.
Red blood cell membrane loss in patients with HS occurs at the reticulocyte stage, 22 25, 26 Second, the treatment will affect the hemocyte parameters; for instance, HS can be effectively improved after splenectomy, and the anemia in patients with thalassemia can be effectively improved after hematopoietic stem cell transplantation or blood transfusion. 27 Consequently, the data we adopt in this research are all the examination results of the patients done for a clear diagnosis on admission, and others should take the effect of treatment into consideration when they use our research results for reference.
In conclusion, increased MCHC, decreased MRV, MSCV-MCV < 0, and increased Ret without increased IRF are characteristic blood cell parameters in HS. Diagnostic guidelines already include MCHC as a criterion for early HS screening, but its diagnostic sensitivity and specificity are not ideal. Nevertheless, it provides a simple and feasible method in hospitals not equipped to perform reticulocyte detection. MSCV-MCV < 0 and MRV < 96.1 fl are valuable indices with wide application prospects for the differential diagnosis of HS from G6PD deficiency, THAL, and AIHA. Given the widespread use of fully automated hematology analyzers, these blood cell parameters represent potentially valuable tools for the preliminary screening and differential diagnosis of HS.
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